Indacaterol/glycopyrronium bromide regulatory update

Novartis submitted a regulatory application to EMA for QVA149 to treat chronic obstructive pulmonary disease (COPD). QVA149 is a fixed-dose combination of NVA237, an inhaled long-acting muscarinic receptor antagonist (LAMA), and indacaterol, a long-acting adrenergic receptor beta 2 agonist (LABA). The submission triggers a $5 million milestone payment each to Sosei and Vectura. Novartis has worldwide rights to develop and commercialize NVA237 from the companies under a 2005 deal (see BioCentury, April 18, 2005). ...